Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to $1.2 billion.

  • Ultragenyx Pharmaceutical's Liabilities and Shareholders Equity fell 2261.61% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 billion, marking a year-over-year decrease of 1079.45%. This contributed to the annual value of $1.5 billion for FY2024, which is 83.45% up from last year.
  • Per Ultragenyx Pharmaceutical's latest filing, its Liabilities and Shareholders Equity stood at $1.2 billion for Q3 2025, which was down 2261.61% from $1.3 billion recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Liabilities and Shareholders Equity registered a high of $1.6 billion during Q3 2022, and its lowest value of $1.2 billion during Q3 2025.
  • In the last 5 years, Ultragenyx Pharmaceutical's Liabilities and Shareholders Equity had a median value of $1.5 billion in 2021 and averaged $1.4 billion.
  • In the last 5 years, Ultragenyx Pharmaceutical's Liabilities and Shareholders Equity skyrocketed by 2956.87% in 2021 and then plummeted by 2349.95% in 2023.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Liabilities and Shareholders Equity (Quarter) stood at $1.5 billion in 2021, then rose by 1.51% to $1.5 billion in 2022, then dropped by 3.52% to $1.5 billion in 2023, then grew by 0.83% to $1.5 billion in 2024, then dropped by 20.82% to $1.2 billion in 2025.
  • Its last three reported values are $1.2 billion in Q3 2025, $1.3 billion for Q2 2025, and $1.3 billion during Q1 2025.